ImmunoGen Inc

ImmunoGen — FY2016 Earnings Presentation

22 slides from ImmunoGen's earnings presentation, Aug 4, 2016

  1. Slide 1: Carol Hausner, Investor Relations & Corporate Communications

    Executive Director, Investor Relations & Corporate Communications Carol Hausner 2

  2. Slide 2: Forward-Looking Statements

    These slides include forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen's expectations related to: the occurrence, timing and outcome of potential pre-clinical, clinical and regulatory events related to the Company's and

  3. Slide 3: President and Chief Executive Officer Mark Enyedy

    President and Chief Executive Officer Mark Enyedy 4

  4. Slide 4: ImmunoGen Today: Positioned for Sustainable Value Creation

    ImmunoGen Today: Positioned for Sustainable Value Creation 5 Leadership in antibody-drug conjugates (ADCs) Lead program entering Phase 3 before year end Platform generating novel clinical candidates Technology validated clinically and through partnerships Strong cash position Experienced management

  5. Slide 5: Strategic Direction & Priorities

    Strategic Direction & Priorities 6 Platinum-resistant ovarian cancer Execute on speed-to-market for mirvetuximab soravtansine IMGN779, IMGN632, IMGN529 Accelerate earlier-stage portfolio Payloads, linkers, methods of conjugation Continue to drive innovation in ADCs as cancer therapies Lever partners

  6. Slide 6: Leadership in ADCs Building Momentum

    Leadership in ADCs Building Momentum ImmunoGen Programs Preclinical Phase 1 Phase 2 Recent Achievements Mirvetuximab soravtansine Ovarian - monotherapy Met with FDA; Advancing to Phase 3 Ovarian - combination Opened Avastin® Phase 2 cohort IMGN529 DLBCL - combination Initiated Phase 2 Coltuximab rav

  7. Slide 7: Driving ADC Innovations that Produce Results

    8 Driving ADC Innovations that Produce Results Our Competitive Advantage The most comprehensive, validated technology portfolio in the industry Linkers Payloads Conjugation Clinical Validation Ongoing Non-cleavable Tubulin-acting DM1 Lysine Kadcyla® Approved, survival benefit (EMILIA) Herceptin-inse

  8. Slide 8: Lever Partnerships to Expand Impact of Innovations

    Lever Partnerships to Expand Impact of Innovations Enabling Our Technology to Benefit More Patients Partner Programs (active, disclosed) Phase 1 Phase 2 Phase 3 Marketed KADCYLA Anetumab ravtansine Indatuximab ravtansine Isatuximab SAR566658 SAR408701 SAR428926 AMG XXX PCA062 LY3076226 CX-2009 LY307

  9. Slide 9: EVP and Chief Development Officer Dr. Charles Morris

    EVP and Chief Development Officer Dr. Charles Morris 10

  10. Slide 10: Execute on Speed-to-Market for Lead Program Mirvetuximab Soravtansine

    Execute on Speed-to-Market for Lead Program Mirvetuximab Soravtansine 11 First ADC to enter registration testing for ovarian cancer MOA distinct from other approaches (PARPs, I/Os, Avastin ) Different clinical profile 1WHO GLOBOCAN 2012, ACS Cancer Facts and Figures. 2Published data and prescribing

  11. Slide 11: Mirvetuximab Soravtansine Ready for Phase 3

    Mirvetuximab Soravtansine Ready for Phase 3 12 Data presented at ASCO 2016 (abstract #5567) Tumor cells with 2+/3+ FRα expression High: at least 75%; Medium: 50-74%; Low: 25-49% Positive meeting with FDA Sizeable safety database Single-agent activity Defined population ≤5 prior regimens ≥ low FRα ≤3

  12. Slide 12: Mirvetuximab Soravtansine FORWARD I Phase 3 Trial

    Mirvetuximab Soravtansine FORWARD I Phase 3 Trial 13 Mirvetuximab soravtansine Physician’s choice single agent chemo* with platinum-resistant ovarian cancer treated with up to 3 prior regimens; high or medium FRα levels *Pegylated liposomal doxorubicin (PLD), topotecan, weekly paclitaxel. 333 patien

  13. Slide 13: Mirvetuximab Soravtansine FORWARD II: Expanding for Ovarian Cancer

    Mirvetuximab Soravtansine FORWARD II: Expanding for Ovarian Cancer 14 Platinum-based regimen Potential for Avastin+paclitaxel Once platinum-resistant Single agent chemotherapy Recurrence Treatment paradigm in US Phase 1/2 trial, Combination regimens to benefit more patients, longer Registration tria

  14. Slide 14: Mirvetuximab Soravtansine Combination Regimens in Ovarian Cancer

    + PLD Extensive use for ovarian cancer Mirvetuximab Soravtansine Combination Regimens in Ovarian Cancer 15 ClinicalTrials.gov identifier: NCT02606305 PLD = pegylated liposomal doxorubicin Keytruda® is a registered trademark of Merck & Co., Inc. Patients with FRα-positive ovarian cancer + Avastin Sta

  15. Slide 15: Accelerate Earlier-Stage Portfolio Clinical Trials Initiated

    Accelerate Earlier-Stage Portfolio 2 Clinical Trials Initiated 16 Targets CD33; deploys lead IGN Phase 1 testing initiated 2Q2016 IMGN779 – New Class of ADC for AML IMGN529 – Striking Synergy with Rituxan Preclinically ASH 2015 abstract #1548; ICML 2015 abstract P-274 Rituxan® is a registered tradem

  16. Slide 16: EVP and Chief Financial Officer David Johnston

    EVP and Chief Financial Officer David Johnston 17

  17. Slide 17: Financials

    Financials *FY2015 includes $20 MM upfront payment from Takeda technology access agreement. **FY2015 includes approx. $194 MM net proceeds from Kadcyla royalty monetization transaction received April 2015. FY2016 includes approx. $97 MM net proceeds from $100 MM convertible debt financing in June 20

  18. Slide 18: President and Chief Executive Officer Mark Enyedy

    President and Chief Executive Officer Mark Enyedy 19

  19. Slide 19: Anticipated Events

    Mirvetuximab soravtansine FORWARD I registration trial Meet with FDA ( ) Initiation (4Q2016) FORWARD II Phase 1b/2 Avastin expansion cohort open ( ) Keytruda cohort open (3Q2016) First data (2Q2017) Earlier-stage portfolio IMGN779 Phase 1 initiation ( ) First clinical data (2017) IMGN632 – preclinic

  20. Slide 20: ImmunoGen Today: Positioned for Sustainable Value Creation

    ImmunoGen Today: Positioned for Sustainable Value Creation 21 Cutting edge technology in growing field Rich pipeline of differentiated product candidates Enhanced financial resources Experienced team Strong partnerships

  21. Slide 21: ImmunoGen Today: Positioned for Sustainable Value Creation

    ImmunoGen Today: Cutting edge technology in growing field Positioned for Sustainable . Rich pipeline of differentiated product candidates Value Creation Enhanced financial resources Strong partnerships IMMUNOGEN

  22. Slide 22: Q&A

    Q&A Carol Hausner IMMUNOGEN

ImmunoGen — FY2016 Earnings Presentation on 6ix